Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy.

Barzi A, Lara PN Jr, Tsao-Wei D, Yang D, Gill IS, Daneshmand S, Klein EA, Pinski JK, Penson DF, Quinn DI, Sadeghi S.

Cancer. 2019 Nov 1;125(21):3853-3863. doi: 10.1002/cncr.32290. Epub 2019 Aug 9.

PMID:
31398279
2.

Osteoporosis in colorectal cancer survivors: analysis of the linkage between SWOG trial enrollees and Medicare claims.

Barzi A, Hershman DL, Till C, Barlow WE, Ramsey S, Lenz HJ, Hochster HS, Unger JM.

Arch Osteoporos. 2019 Jul 28;14(1):83. doi: 10.1007/s11657-019-0629-7.

PMID:
31352608
3.

Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.

Bekaii-Saab TS, Ou FS, Ahn DH, Boland PM, Ciombor KK, Heying EN, Dockter TJ, Jacobs NL, Pasche BC, Cleary JM, Meyers JP, Desnoyers RJ, McCune JS, Pedersen K, Barzi A, Chiorean EG, Sloan J, Lacouture ME, Lenz HJ, Grothey A.

Lancet Oncol. 2019 Aug;20(8):1070-1082. doi: 10.1016/S1470-2045(19)30272-4. Epub 2019 Jun 28.

PMID:
31262657
4.

Real-World Outcomes and Factors Associated With the Second-Line Treatment of Patients With Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma.

Barzi A, Hess LM, Zhu YE, Liepa AM, Sugihara T, Beyrer J, Chao J.

Cancer Control. 2019 Jan-Dec;26(1):1073274819847642. doi: 10.1177/1073274819847642.

5.

Tertiary Care Multidisciplinary Teams Associated with Improved Survival in Rectal Cancer Patients: A Comparative Study.

Tambe B, Wang CV, Noren E, Duldulao MP, Barzi A, Lee SW.

Am Surg. 2018 Oct 1;84(10):1645-1649.

PMID:
30747687
6.

Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials.

Chau I, Fuchs CS, Ohtsu A, Barzi A, Liepa AM, Cui ZL, Hsu Y, Al-Batran SE.

Eur J Cancer. 2019 Jan;107:115-123. doi: 10.1016/j.ejca.2018.11.013. Epub 2018 Dec 14.

7.

Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial.

Suenaga M, Stintzing S, Cao S, Zhang W, Yang D, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Schirripa M, Soni S, Barzi A, Heinemann V, Lenz HJ.

Eur J Cancer. 2019 Jan;107:100-114. doi: 10.1016/j.ejca.2018.11.019. Epub 2018 Dec 14.

PMID:
30554073
8.

Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab.

Xu Y, Hay JW, Barzi A.

Cost Eff Resour Alloc. 2018 Nov 12;16:30. doi: 10.1186/s12962-018-0132-9. eCollection 2018.

9.

Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients.

Suenaga M, Cao S, Zhang W, Yang D, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Schirripa M, Soni S, Barzi A, Yamaguchi T, Lenz HJ.

Int J Cancer. 2019 May 15;144(10):2567-2577. doi: 10.1002/ijc.31968. Epub 2018 Dec 14.

PMID:
30411783
10.

Biomarker-driven targeted therapies for gastric/gastro-esophageal junction malignancies.

Kim S, Barzi A, Rajdev L.

Semin Oncol. 2018 Jun;45(3):133-150. doi: 10.1053/j.seminoncol.2018.03.001. Epub 2018 Mar 20. Review.

PMID:
30262395
11.

Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States.

Cho SK, Hay JW, Barzi A.

Clin Colorectal Cancer. 2018 Dec;17(4):e751-e761. doi: 10.1016/j.clcc.2018.08.003. Epub 2018 Aug 24.

PMID:
30228027
12.

Secondary Germline Finding in Liquid Biopsy of a Deceased Patient; Case Report and Review of the Literature.

Veyseh M, Ricker C, Espenschied C, Raymond V, D'Souza A, Barzi A.

Front Oncol. 2018 Jul 9;8:259. doi: 10.3389/fonc.2018.00259. eCollection 2018.

13.

Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer.

Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Cremolini C, Lonardi S, Bergamo F, Ning Y, Yamamoto N, Okazaki S, Berger MD, Miyamoto Y, Gopez R Jr, Barzi A, Yamaguchi T, Stintzing S, Heinemann V, Loupakis F, Falcone A, Lenz HJ.

Pharmacogenomics J. 2018 Sep;18(5):623-632. doi: 10.1038/s41397-018-0030-8. Epub 2018 Jun 21.

14.

Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types.

Ishiba T, Hoffmann AC, Usher J, Elshimali Y, Sturdevant T, Dang M, Jaimes Y, Tyagi R, Gonzales R, Grino M, Pinski JK, Barzi A, Raez LE, Eberhardt WE, Theegarten D, Lenz HJ, Uetake H, Danenberg PV, Danenberg K.

Biochem Biophys Res Commun. 2018 Jun 7;500(3):621-625. doi: 10.1016/j.bbrc.2018.04.120. Epub 2018 Apr 30.

PMID:
29679564
15.

Outlooks on Epstein-Barr virus associated gastric cancer.

Naseem M, Barzi A, Brezden-Masley C, Puccini A, Berger MD, Tokunaga R, Battaglin F, Soni S, McSkane M, Zhang W, Lenz HJ.

Cancer Treat Rev. 2018 May;66:15-22. doi: 10.1016/j.ctrv.2018.03.006. Epub 2018 Mar 31. Review.

16.

Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib.

Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Ning Y, Cremolini C, Antoniotti C, Borelli B, Mashima T, Okazaki S, Berger MD, Miyamoto Y, Gopez R Jr, Barzi A, Lonardi S, Yamaguchi T, Falcone A, Loupakis F, Lenz HJ.

Clin Colorectal Cancer. 2018 Jun;17(2):e395-e414. doi: 10.1016/j.clcc.2018.02.010. Epub 2018 Feb 27.

PMID:
29606345
17.

Trends in colorectal cancer mortality in hispanics: a SEER analysis.

Barzi A, Yang D, Mostofizadeh S, Lenz HJ.

Oncotarget. 2017 Oct 19;8(65):108771-108777. doi: 10.18632/oncotarget.21938. eCollection 2017 Dec 12.

18.

Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.

Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Dadduzio V, Salvatore L, Borelli B, Pietrantonio F, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Gopez R Jr, Barzi A, Yamaguchi T, Loupakis F, Lenz HJ.

Eur J Cancer. 2017 Nov;86:197-206. doi: 10.1016/j.ejca.2017.08.033. Epub 2017 Oct 6.

PMID:
28992563
19.

Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.

Okazaki S, Schirripa M, Loupakis F, Cao S, Zhang W, Yang D, Ning Y, Berger MD, Miyamoto Y, Suenaga M, Iqubal S, Barzi A, Cremolini C, Falcone A, Battaglin F, Salvatore L, Borelli B, Helentjaris TG, Lenz HJ.

Cancer. 2017 Nov 15;123(22):4506-4514. doi: 10.1002/cncr.30880. Epub 2017 Jul 14.

20.

DNA mismatch repair deficiency and hereditary syndromes in Latino patients with colorectal cancer.

Ricker CN, Hanna DL, Peng C, Nguyen NT, Stern MC, Schmit SL, Idos GE, Patel R, Tsai S, Ramirez V, Lin S, Shamasunadara V, Barzi A, Lenz HJ, Figueiredo JC.

Cancer. 2017 Oct 1;123(19):3732-3743. doi: 10.1002/cncr.30790. Epub 2017 Jun 22.

21.

Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.

Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Murgioni S, Rossini D, Marmorino F, Mennitto A, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Gopez R Jr, Barzi A, Yamaguchi T, Loupakis F, Lenz HJ.

Ann Oncol. 2017 May 1;28(5):1015-1022. doi: 10.1093/annonc/mdx035.

22.

Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.

Schirripa M, Zhang W, Heinemann V, Cao S, Okazaki S, Yang D, Loupakis F, Berger MD, Ning Y, Miyamoto Y, Suenaga M, Gopez RF, West JD, Hanna D, Barzi A, Falcone A, Stintzing S, Lenz HJ.

Int J Cancer. 2017 Jul 15;141(2):383-392. doi: 10.1002/ijc.30715. Epub 2017 May 10.

23.

Access to high-volume surgeons and the opportunity cost of performing radical prostatectomy by low-volume providers.

Barzi A, Klein EA, Daneshmand S, Gill I, Quinn DI, Sadeghi S.

Urol Oncol. 2017 Jul;35(7):459.e15-459.e24. doi: 10.1016/j.urolonc.2017.01.021. Epub 2017 Mar 9.

PMID:
28284890
24.

Colorectal cancer statistics, 2017.

Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A.

CA Cancer J Clin. 2017 May 6;67(3):177-193. doi: 10.3322/caac.21395. Epub 2017 Mar 1.

25.

Comparative effectiveness of screening strategies for colorectal cancer.

Barzi A, Lenz HJ, Quinn DI, Sadeghi S.

Cancer. 2017 May 1;123(9):1516-1527. doi: 10.1002/cncr.30518. Epub 2017 Jan 24.

26.

Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers.

Fujii T, Barzi A, Sartore-Bianchi A, Cassingena A, Siravegna G, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Huang HJ, Veronese S, Di Nicolantonio F, Pingle S, Vibat CRT, Hancock S, Berz D, Melnikova VO, Erlander MG, Luthra R, Kopetz ES, Meric-Bernstam F, Siena S, Lenz HJ, Bardelli A, Janku F.

Clin Cancer Res. 2017 Jul 15;23(14):3657-3666. doi: 10.1158/1078-0432.CCR-16-2592. Epub 2017 Jan 17.

27.

Stomach Cancer Disparity among Korean Americans by Tumor Characteristics: Comparison with Non-Hispanic Whites, Japanese Americans, South Koreans, and Japanese.

Lee E, Liu L, Zhang J, Stern MC, Barzi A, Hwang A, Kim AE, Hamilton AS, Wu AH, Deapen D.

Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):587-596. doi: 10.1158/1055-9965.EPI-16-0573. Epub 2016 Dec 1.

28.

A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials.

Sebio A, Stintzing S, Heinemann V, Sunakawa Y, Zhang W, Ichikawa W, Tsuji A, Takahashi T, Parek A, Yang D, Cao S, Ning Y, Stremitzer S, Matsusaka S, Okazaki S, Barzi A, Berger MD, Lenz HJ.

Pharmacogenomics J. 2018 Jan;18(1):43-48. doi: 10.1038/tpj.2016.69. Epub 2016 Oct 4.

29.

Metastatic Colorectal Cancer in Hispanics: Treatment Outcomes in a Treated Population.

Shabihkhani M, Yu SS, Yang D, Lin S, Hamilton AS, Lenz HJ, Barzi A.

Clin Colorectal Cancer. 2016 Dec;15(4):e221-e227. doi: 10.1016/j.clcc.2016.03.001. Epub 2016 Mar 31.

PMID:
27553907
30.

Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012.

Berger MD, Yang D, Sunakawa Y, Zhang W, Ning Y, Matsusaka S, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Lenz AM, Bohanes P, Barzi A, Figueiredo JC, Hanna DL, Lenz HJ.

Oncotarget. 2016 Aug 16;7(33):53668-53678. doi: 10.18632/oncotarget.10696.

31.

Prostatectomy at high-volume centers improves outcomes and lowers the costs of care for prostate cancer.

Barzi A, Klein EA, Dorff TB, Quinn DI, Sadeghi S.

Prostate Cancer Prostatic Dis. 2016 Mar;19(1):84-91. doi: 10.1038/pcan.2015.56. Epub 2015 Dec 15.

PMID:
26666409
32.

We Don't Know What We Don't Know About Adolescent and Young Adult Patients with Familial Adenomatous Polyposis-Related Colorectal Cancer.

Grubman J, Barzi A.

J Adolesc Young Adult Oncol. 2015 Sep;4(3):105-7. doi: 10.1089/jayao.2015.0008. No abstract available.

33.

Lost in Translation: The Patient-Physician Relationship in the Molecular Era.

Grubman J, Barzi A.

J Palliat Med. 2015 Nov;18(11):987-8. doi: 10.1089/jpm.2015.0170. Epub 2015 Sep 29. No abstract available.

PMID:
26418297
34.

Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach.

Ning Y, Hanna DL, Zhang W, Mendez A, Yang D, El-Khoueiry R, Matsusaka S, Sunakawa Y, Stremitzer S, Parekh A, Okazaki S, Berger MD, Barzi A, Lenz HJ.

Mol Cancer Ther. 2015 Oct;14(10):2401-8. doi: 10.1158/1535-7163.MCT-15-0359. Epub 2015 Jul 30.

35.

Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases.

Stremitzer S, Zhang W, Yang D, Ning Y, Stintzing S, Sunakawa Y, Sebio A, Yamauchi S, Matsusaka S, Parekh A, Barzi A, El-Khoueiry R, Stift J, Wrba F, Gruenberger T, Lenz HJ.

Ann Oncol. 2015 Aug;26(8):1728-33. doi: 10.1093/annonc/mdv224. Epub 2015 May 8.

36.

Comparative effectiveness of screening strategies for Lynch syndrome.

Barzi A, Sadeghi S, Kattan MW, Meropol NJ.

J Natl Cancer Inst. 2015 Mar 20;107(4). pii: djv005. doi: 10.1093/jnci/djv005. Print 2015 Apr.

37.

Cost-effectiveness of genomic testing for colorectal cancer: are we there yet?

Barzi A, Lenz HJ.

Oncology (Williston Park). 2015 Mar;29(3):183-4; 186. No abstract available.

38.

Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy.

Maus MK, Hanna DL, Stephens CL, Astrow SH, Yang D, Grimminger PP, Loupakis F, Hsiang JH, Zeger G, Wakatsuki T, Barzi A, Lenz HJ.

Pharmacogenomics J. 2015 Aug;15(4):354-62. doi: 10.1038/tpj.2014.73. Epub 2014 Dec 23.

39.

Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer.

Sunakawa Y, Stremitzer S, Cao S, Zhang W, Yang D, Wakatsuki T, Ning Y, Yamauchi S, Stintzing S, Sebio A, El-Khoueiry R, Matsusaka S, Parekh A, Barzi A, Azuma M, Watanabe M, Koizumi W, Lenz HJ.

Ann Oncol. 2015 Feb;26(2):332-9. doi: 10.1093/annonc/mdu542. Epub 2014 Nov 18.

40.

Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients.

Sunakawa Y, Wakatsuki T, Yang D, Zhang W, Ning Y, Stintzing S, Stremitzer S, Yamauchi S, Sebio A, El-khoueiry R, Iqbal S, Barzi A, Gerger A, Stotz M, Azuma M, Watanabe M, Koizumi W, Lenz HJ.

Pharmacogenet Genomics. 2014 Dec;24(12):588-96. doi: 10.1097/FPC.0000000000000091.

41.

Single nucleotide polymorphisms in AREG and EREG are prognostic biomarkers in locally advanced gastric cancer patients after surgery with curative intent.

Wakatsuki T, Stintzing S, Zhang W, Yang D, Azuma M, Ning Y, Yamauchi S, Matsusaka S, Volz NB, Sunakawa Y, Koizumi W, Watanabe M, Barzi A, El Khoueiry AB, Shah MA, Lenz HJ.

Pharmacogenet Genomics. 2014 Nov;24(11):539-47. doi: 10.1097/FPC.0000000000000087.

42.

Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results.

Semrad T, Barzi A, Lenz HJ, Hutchins IM, Kim EJ, Gong IY, Tanaka M, Beckett L, Holland W, Burich RA, Snyder-Solis L, Mack P, Lara PN Jr.

Int J Clin Oncol. 2015 Jun;20(3):518-24. doi: 10.1007/s10147-014-0730-2. Epub 2014 Aug 5.

43.

Angiogenesis in esophageal and gastric cancer: a paradigm shift in treatment.

Barzi A, Thara E.

Expert Opin Biol Ther. 2014 Sep;14(9):1319-32. doi: 10.1517/14712598.2014.921677. Epub 2014 May 31. Review.

PMID:
24881691
44.

Timeliness of adjuvant chemotherapy for stage III adenocarcinoma of the colon: a measure of quality of care.

Yu S, Shabihkhani M, Yang D, Thara E, Senagore A, Lenz HJ, Sadeghi S, Barzi A.

Clin Colorectal Cancer. 2013 Dec;12(4):275-9. doi: 10.1016/j.clcc.2013.08.002.

PMID:
24188686
45.

Molecular pathways: Estrogen pathway in colorectal cancer.

Barzi A, Lenz AM, Labonte MJ, Lenz HJ.

Clin Cancer Res. 2013 Nov 1;19(21):5842-8. doi: 10.1158/1078-0432.CCR-13-0325. Epub 2013 Aug 21. Review.

46.

Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States.

Wakatsuki T, LaBonte MJ, Bohanes PO, Zhang W, Yang D, Azuma M, Barzi A, Ning Y, Loupakis F, Saadat S, Volz N, Stintzing S, El-Khoueiry R, Koizumi W, Watanabe M, Shah M, Stebbing J, Giamas G, Lenz HJ.

Mol Cancer Ther. 2013 Oct;12(10):2261-72. doi: 10.1158/1535-7163.MCT-12-1134. Epub 2013 Aug 5.

47.

Angiogenesis-related agents in esophageal cancer.

Barzi A, Lenz HJ.

Expert Opin Biol Ther. 2012 Oct;12(10):1335-45. doi: 10.1517/14712598.2012.707180. Epub 2012 Aug 4. Review.

PMID:
22860627
48.

Screening for Lynch syndrome in the general population-letter.

Sadeghi S, Barzi A, Kattan MW, Meropol NJ.

Cancer Prev Res (Phila). 2011 Mar;4(3):471; author reply 472. doi: 10.1158/1940-6207.CAPR-10-0392. No abstract available. Erratum in: Cancer Prev Res (Phila). 2011 May;4(5):774.

49.
50.

Myelodysplastic syndromes: a practical approach to diagnosis and treatment.

Barzi A, Sekeres MA.

Cleve Clin J Med. 2010 Jan;77(1):37-44. doi: 10.3949/ccjm.77a.09069. Review.

PMID:
20048028

Supplemental Content

Support Center